Can hyperoxaluria cause kidney damage in women with recurrent pyelonephritis?

Stepanova, N.; Kolesnyk, М.; Driianska, V.; Korol, L.

doi:10.1016/s1569-9056(19)30140-x

Cited by 3 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tasian and colleagues (16) have identified a strong association between oral antibiotics and the risk of nephrolithiasis which remains elevated for up to five years from antibiotic exposure. These results also accord with our earlier studies, which reported a strong association between antibiotics administration, intestinal barrier dysfunction and hyperoxaluria formation (15,18,25). In view of all that has been mentioned so far, one may suppose that Lactobacillus and Bifidobacterium deficiency leads to intestinal barrier dysfunction, violation of oxalate transport mechanisms in intestinal epithelium (both secretion and absorption) and a decrease in total ODA in fecal microbiota in PD patients.…”

Section: Discussionsupporting

confidence: 92%

“…However, it is important to note that the indirect and, in fact, the opposite result was obtained in our study: the higher total ODA level in fecal microbiota in ESRD patients was, the higher UOx level occurred. This hyperoxaluric phenomenon in dialysis patients is completely different from existing data in healthy subjects and kidney stone disease patients in whom hyperoxaluria is one of the most significant risk factors for nephrolithiasis (1,3,8) and CKD progression (25,33). The findings observed in this study mirror those of the previous studies that have demonstrated that oxalate removal rate in ESRD patients is significantly greater compared with normal subjects (4,5,27).…”

Section: Discussionmentioning

confidence: 61%

“…Oxalate in healthy subjects is eliminated through urine excretion (85% to 90%), forming insoluble calcium oxalate and elimination in feces or degradation by the gastrointestinal (GIT) oxalate-degrading bacteria (15% to 10%) (1,8). Elevated POx concentration and decreased UOx excretion levels are associated with the progression of chronic kidney disease (CKD) (23)(24)(25). In uremic and/ or anuric conditions, dialysis assumes the main approach for oxalate removal (2,4,24).…”

Section: Discussionmentioning

confidence: 99%

“…In uremic and/ or anuric conditions, dialysis assumes the main approach for oxalate removal (2,4,24). Nevertheless, despite a homogenous patient population and the standardized dialysis regimen, intraindividual predialysis POx concentration level varies from 1.8 mg/L (20 µmol/L) to 5.4 mg/L (60 µmol/L) in different research (2,(24)(25)(26). Considering the fact that oxalate homeostasis only marginally depends on dietary oxalate intake (8) and cannot be excreted by the kidneys in ESRD patients, an issue arises why ESRD patients have significant differences in POx concentration under the same treatment conditions.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

A potential role of fecal oxalate-degrading activity in oxalate homeostasis in end-stage renal disease patients; a descriptive pilot study

et al. 2021

View full text Add to dashboard Cite

Introduction: End-stage renal disease (ESRD) patients have significant differences in plasma oxalic acid (POx) concentration under the same treatment conditions. Objectives: In the present study, we adopted the method of redoximetric titration with a KMnO4 solution to evaluate the effect of total fecal oxalate-degrading activity (ODA) on oxalate homeostasis in ESRD patients which has never been reported before. Patients and Methods: A total of 56 participants were enrolled in this cross-sectional pilot study, including 24 healthy volunteers (a control reference group) and 32 ESRD patients. Among the ESRD patients, there were 21 hemodialysis (HD) and 11 peritoneal dialysis (PD) patients. Total ODA in fecal samples as well as POx concentration, daily urinary oxalate (UOx) and PD effluent oxalate excretion were determined. Cohen’s d was computed to calculate the effect size using post-hoc analysis. Results: Total ODA in fecal microbiota ranged from -23 to 24%/0.01 g of feces and was statistically higher in healthy volunteers compared with the ESRD patients. The ESRD patients with positive total fecal ODA status had higher UOx excretion level and lower POx concentration compared with the patients with negative total fecal ODA status. Cohen’s d effect size was 1.99 and 1.05, respectively. Total fecal ODA was an independent risk factor associated with POx elevation in the ESRD patients. Conclusion: Our pilot study firstly demonstrated a potential role of total fecal ODA in oxalate homeostasis in ESRD patients. The results might be useful for determining sample size considerations and providing groundwork for future research projects.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A potential role of fecal oxalate-degrading activity in oxalate homeostasis in end-stage renal disease patients; a descriptive pilot study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…2021 Jun 25. [Epub ahead of print] inflammation [7][8][9], and thus a high risk of CVD independent of its cause [10,11]. It has been demonstrated that plasma oxalic acid (POx) concentration increases according to the progression of chronic kidney disease (CKD) and reaches its highest level in ESRD patients [12,13].…”

Section: Introductionmentioning

confidence: 99%

Plasma oxalic acid and cardiovascular risk in end-stage renal disease patients: a prospective, observational cohort pilot study

Stepanova

Driianska

Korol

et al. 2022

Korean J Intern Med

View full text Add to dashboard Cite

Background/Aims: It was hypothesized that oxalate might be strongly involved in atherogenesis and the inflammatory pathway that could result in an increased risk of cardiovascular disease (CVD) in end-stage renal disease (ESRD) patients. Therefore, this study aimed to address two primary research questions: to characterize the lipid profile and the pattern of pro-inflammatory cytokines according to plasma oxalic acid (POx) concentration in ESRD patients; to evaluate the potential role of elevated POx concentration in the development of CVD risk. Methods: A total of 73 participants were enrolled in this prospective, observational cohort pilot study. Among them, there were 50 ESRD patients and 23 healthy volunteers. The lipid profile and the pro-inflammatory cytokines were analyzed according to the distribution of POx concentration into tertiles. After the clinical examination, 29 hemodialysis patients and 21 peritoneal dialysis patients without prevalent CVD were observed for CVD events for 2 years. The Cox regression analysis and a set of different types of sensitivity analyses were used to determine whether elevated POx was associated with an increased risk of CVD. Results: An increasing trend in the atherogenic lipoprotein fractions and the pro-inflammatory markers as well as a linear decrease in high-density lipoprotein was significantly associated with elevated POx. POx concentration ≥ 62.9 µmol/L was significantly associated with CVD events independently of other examined CVD risk factors. Conclusions: This pilot study firstly demonstrated a potential contribution of POx to atherogenesis, inflammation and CVD risk in ESRD patients.

show abstract

Hyperoxaluria; a risk factor or a consequence of recurrent pyelonephritis?

Stepanova

2020

J Nephropathol

View full text Add to dashboard Cite

Can hyperoxaluria cause kidney damage in women with recurrent pyelonephritis?

Cited by 3 publications

References 0 publications

A potential role of fecal oxalate-degrading activity in oxalate homeostasis in end-stage renal disease patients; a descriptive pilot study

A potential role of fecal oxalate-degrading activity in oxalate homeostasis in end-stage renal disease patients; a descriptive pilot study

Plasma oxalic acid and cardiovascular risk in end-stage renal disease patients: a prospective, observational cohort pilot study

Hyperoxaluria; a risk factor or a consequence of recurrent pyelonephritis?

Contact Info

Product

Resources

About